The burden and management of FXIII deficiency

Haemophilia

Volumn 20, Issue 6, 2014, Pages 733-740

  de Jager, Tim ^a   Pericleous, L ^b   Kokot Kierepa, M ^c   Naderi, M ^d   Karimi, M ^e  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b NOVO NORDISK A S   (Denmark)

^c Novo Nordisk FemCare AG   (Switzerland)

^d ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Burden of illness; Cost of illness; Disease management; Factor XIII deficiency; Review

Indexed keywords

BLOOD CLOTTING FACTOR 13 CONCENTRATE; CATRIDECACOG;

BLOOD CLOTTING FACTOR 13 DEFICIENCY; BRAIN HEMORRHAGE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE SEVERITY; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; LENGTH OF STAY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SPONTANEOUS ABORTION; SUBSTITUTION THERAPY; SYSTEMATIC REVIEW; WOUND HEALING IMPAIRMENT; COST OF ILLNESS; DISEASE MANAGEMENT; FACTOR XIII DEFICIENCY; META ANALYSIS; QUESTIONNAIRE; REGISTER;

COST OF ILLNESS; DISEASE MANAGEMENT; FACTOR XIII DEFICIENCY; HEALTH CARE COSTS; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES; REGISTRIES;

EID: 84928825166     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12474     Document Type: Review

References (47)

1. Ivaskevicius V, Seitz R, Kohler HP et al. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost, Schattauer 2007; 97: 914-21.
2. Asahina T, Kobayashi T, Takeuchi K, Kanayama N. Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature. Obstet Gynecol Surv 2007; 62: 255-60.
3. Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek L. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9: 1404-6.
4. Boehlen F, Casini A, Chizzolini C et al. Acquired factor XIII deficiency: a therapeutic challenge. Thromb Haemost 2013; 109: 1-9.
5. Todd T, Perry DJ. A review of long-term prophylaxis in the rare inherited coagulation factor deficiencies. Haemophilia 2010; 16: 569-83.
6. Bolton-Maggs PHB, Perry DJ, Chalmers EA et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
7. Peyvandi F, Palla R, Menegatti M et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10: 615-21.
8. Viswabandya A, Baidya S, Nair SC et al. Correlating clinical manifestations with factor levels in rare bleeding disorders: a report from Southern India. Haemophilia 2012; 18: e195-200.
9. Anwar R, Miloszewski KJ. Factor xiii deficiency. Br J Haematol. 1999; 107: 468-84.
10. Acharya SS, Coughlin A, Dimichele DM. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2: 248-56.
11. McGuire AJ, Raikou M, Whittle I, Christensen MC. Long-term mortality, morbidity and hospital care following intracerebral hemorrhage: an 11-year cohort study. Cerebrovasc Dis 2007; 23: 221-8.
12. Naderi M, Eshghi P, Cohan N, Miri-Moghaddam E, Yaghmaee M, Karimi M. Successful delivery in patients with FXIII deficiency receiving prophylaxis: report of cases in Iran. Haemophilia 2012; 18: 773-6.
13. Sharief L, Kadir RA. Congenital FXIII in women; a systematic review of literature. Haemophilia 2013; 19: e349-57.
14. Lak M, Peyvandi F, Ali Sharifian A, Karimi K, Mannucci PM. Pattern of symptoms in Iranian patients with severe factor XIII deficiency. J Thromb Haemost 2003; 1: 1852-3
15. Brazier JE, Harper R, Jones NM et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305: 160-4.
16. Solovieva S. Clinical severity of disease, functional disability and health-related quality of life. Three-year follow-up study of 150 Finnish patients with coagulation disorders. Haemophilia 2001; 7: 53-63.
17. Ronne-Engström E, Enblad P, Lundström E. Health-related quality of life at median 12 months after aneurysmal subarachnoid hemorrhage, measured with EuroQoL-5D. Acta Neurochir (Wien) 2013; 155: 587-93.
18. Meyer B, Ringel F, Winter Y et al. Healthrelated quality of life in patients with subarachnoid haemorrhage. Cerebrovasc Dis 2010; 30: 423-31.
19. Wang H-M, Beyer M, Gensichen J, Gerlach FM. Health-related quality of life among general practice patients with differing chronic diseases in Germany: cross sectional survey. BMC Public Health 2008; 8: 246.
20. Eshghi P, Mahjour SB, Naderi M, Dehbozorgian J, Karimi M. Long-term prophylaxis in patients with factor XIII deficiency complicated by intracranial haemorrhage in Iran. Haemophilia 2010; 16: 383-5.
21. Revel-Vilk S, Golomb MR, Achonu C et al. Effect of intracranial bleeds on the health and quality of life of boys with hemophilia. J Pediatr 2004; 144: 490-5.
22. Christerson S, Strömberg B. Stroke in Swedish children II: long-term outcome. Acta Paediatr 2010; 99: 1650-6.
23. Asil T, Celik Y, Sut N et al. Cost of acute ischemic and hemorrhagic stroke in Turkey. Clin Neurol Neurosurg. Elsevier B.V. 2011; 113: 111-14.
24. Russell MW, Joshi AV, Neumann PJ, Boulanger L, Menzin J. Predictors of hospital length of stay and cost in patients with intracerebral hemorrhage. Neurology 2006; 67: 1279-81.
25. Lee WC, Christensen MC, Joshi AV, Pashos CL. Long-term cost of stroke subtypes among Medicare beneficiaries. Cerebrovasc Dis 2007; 23: 57-65.
26. Navarrete-Navarro P, Hart WM, Lopez-Bastida J, Christensen MC. The societal costs of intracerebral hemorrhage in Spain. Eur J Neurol 2007; 14: 556-62.
27. Weimar C, Weber C, Wagner M et al. Management patterns and health care use after intracerebral hemorrhage. A cost-of-illness study from a societal perspective in Germany. Cerebrovasc Dis 2003; 15: 29-36.
28. Cadilhac DA, Carter R, Thrift AG, Dewey HM. Estimating the long-term costs of ischemic and hemorrhagic stroke for Australia: new evidence derived from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2009; 40: 915-21.
29. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haemat. Haemophilia 2008; 14: 671-84.
30. Fischer K, Hermans C. The European Principles of Haemophilia Care: a pilot investigation of adherence to the principles in Europe. Haemophilia 2013; 19: 35-43.
31. TM/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thromb Res 2012; 130: S12-14.
32. Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood 2012; 119: 5111-17.
33. De Wee EM, Mauser-Bunschoten EP, Van Der Bom JG et al. Health-related quality of life among adult patients with moderate and severe von Willebrand disease. J Thromb Haemost 2010; 8: 1492-9.
34. De Wee EM, Fijnvandraat K, de Goede-Bolder A et al. Impact of von Willebrand disease on health-related quality of life in a pediatric population. J Thromb Haemost 2011; 9: 502-9.
35. Bullinger M, Globe D, Wasserman J, Young NL, von Mackensen S. Challenges of patient-reported outcome assessment in hemophilia care-a state of the art review. Value Heal 2009; 12: 808-20.
36. Aledort L, Bullinger M, von Mackensen S, Wasserman J, Young NL, Globe D. Why should we care about quality of life in persons with haemophilia? Haemophilia 2012; 18: e154-7.
37. Kessler CM. New perspectives in hemophilia treatment. Hematology 2005; 1: 429-35.
38. Lee WC, Joshi AV, Woolford S et al. Physicians' preferences towards coagulation factor concentrates in the treatment of Haemophilia with inhibitors: a discrete choice experiment. Haemophilia 2008; 14: 454-65.
39. Brown TM, Pashos CL, Joshi AV, Lee WC. The perspective of patients with haemophilia with inhibitors and their care givers: preferences for treatment characteristics. Haemophilia 2011; 17: 476-82.
40. Mansouritorghabeh H, Manavifar L, Banihashem A et al. An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran. Blood Transfus. 2012; 1-10.
41. CSL Behring. A 12 Week, Multicenter, Pharmacokinetic and Safety Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency In: ClinicalTrials.gov [Internet, cited 2013 April 15]. Identifier: NCT00883090.
42. Dreyfus M, Barrois D, Borg J-Y et al. Successful long-term replacement therapy with FXIII concentrate (Fibrogammin(®) P) for severe congenital factor XIII deficiency: a prospective multicentre study. J Thromb Haemost 2011; 9: 1264-6.
43. Lusher J, Pipe SW, Alexander S, Nugent D. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia 2010; 16: 316-21.
44. Brackmann HH, Egbring R, Ferster A et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost 1995; 74: 622-5.
45. Lovejoy AE, Reynolds TC, Visich JE et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108: 57-62.
46. Visich J, Zuckerman L, Butine M. Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose study. Thromb Haemost 2005; 94: 802-7.
47. Reynolds TC, Butine MD, Visich JE et al. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers. J Thromb Haemost 2005; 3: 922-8.